In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 4 days of free consultation

 

Ongoing studies with SGLT2 inhibitors: how may new and emerging evidence inform future clinical practice?

Session Know it by heart - New opportunities for cardiologists in the Sodium-Glucose-Co-Transporter 2 (SGLT2) inhibitor era

Speaker Faiez Zannad

Congress : Heart Failure 2019

  • Topic : preventive cardiology
  • Sub-topic : Diabetes and the Heart
  • Session type : Satellite Symposium
  • FP Number : 1401
  • Sponsored by Boehringer Ingelheim & Eli Lilly and Company Alliance
15 views


Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are